David Bridges
An older sibling of the favored diabetes and weight reduction drug semaglutide could assist gradual the development of Alzheimer’s illness. In scientific trial knowledge launched this week, UK scientists have discovered proof that liraglutide can scale back mind shrinkage and cognitive decline in Alzheimer’s sufferers. Semaglutide is already being examined out in bigger Section III trials for the neurodegenerative situation.
Liraglutide and related medicine mimic the hormone GLP-1, which helps regulate our blood sugar and urge for food. It was authorized in 2010 to deal with sort 2 diabetes; in 2014, it was authorized to deal with weight problems. Individuals with poorly managed diabetes are recognized to be at greater threat for Alzheimer’s and different types of dementia, whereas some research in animals have advised that liraglutide can forestall the damaging mind adjustments that happen in Alzheimer’s. So scientists on the Imperial Faculty London determined to conduct a double-blinded, randomized, and placebo-controlled trial of liraglutide for Alzheimer’s.
The trial concerned 204 sufferers recognized with early Alzheimer’s, half of whom got liraglutide. The drug didn’t seem to considerably change folks’s glucose metabolism within the mind, which was the first measure of the examine. However the researchers did discover that individuals on liraglutide skilled an virtually 50% slower decline in mind quantity loss than folks taking placebo over the subsequent 12 months. These on the drug additionally skilled an 18% slower decline in measured cognitive operate throughout that point. The staff’s findings had been introduced this week on the Alzheimer’s Affiliation Worldwide Convention.
This analysis is preliminary; it hasn’t but gone via the peer-review course of. And assuming the outcomes are legitimate, it’s nonetheless not clear precisely how liraglutide is perhaps bettering folks’s brains for the higher. However the researchers do have a number of attainable explanations.
“We expect liraglutide is defending the mind presumably by lowering irritation, reducing insulin resistance and the poisonous results of Alzheimer’s biomarkers or bettering how the mind’s nerve cells talk,” mentioned examine researcher Paul Edison, a professor of neuroscience at Imperial’s Division of Mind Sciences, in an announcement from the college.
Maybe probably the most thrilling a part of this analysis is that stronger GLP-1 medicine have emerged since this examine started, equivalent to semaglutide. Semaglutide (bought underneath the names Ozempic and Wegovy) and the even newer tirzepatide (Mounjaro and Zepbound) have confirmed to be considerably simpler at treating diabetes and weight problems than older GLP-1 drugs like liraglutide. And a examine revealed simply final month has already discovered proof that semaglutide can increase mind well being in folks with sort 2 diabetes.
The makers of each liraglutide and semaglutide, Novo Nordisk, are at the moment conducting two large-scale, placebo-controlled trials to see whether or not semaglutide can enhance the trajectory of individuals recognized with early Alzheimer’s illness. If these outcomes, anticipated to reach inside the subsequent few years, are constructive, they need to result in semaglutide and different GLP-1 medicine turning into the newest software in a rising arsenal of anti-Alzheimer’s drugs.
Daniel Mercer
Ethan Carter
